mtxx
P/E (ttm): 23.64
PERIOD ENDING ...31-Dec-07. 30-Sep-07 .30-Jun-07. 31-Dec-06
Retained Earnings .16,411 . 17,046 ... 10,637 .... 9,990
Total Revenue .....30,802 . 28,576 ... 8,573 .. 36,227
Sale (buy) Stock ..(3,594)..... 42 ..... 259 ..... 931 <--
Net Borrowings .........4 ... (19) .......0... (4,000) <--
..
Qtrly Revenue Growth (yoy): -15.00% <---------bzzzt
Qtrly Earnings Growth (yoy): N/A
Total Debt (mrq): 0 <-------------xlnt
..
Shares Short (Feb08): 844.99K
Shares Short (as of 11-Mar-08): 863.30K
Short % of Float (as of 11-Mar-08): 9.20% <--squeezeable shorts
..
Matrixx Initiatives, Inc. and its subsidiaries engage in the development,
production, marketing, and sale of over-the-counter healthcare products.
It
offers Zicam Cold Remedy nasal gel that reduces the duration and severity
of the common cold; Zicam Cold Remedy Swabs for consumers who dislike
nasal
sprays; and Zicam Cold Remedy Chewables, Zicam Cold Remedy RapidMelts,
Zicam Cold Remedy Oral Mist, Zicam Cold Remedy RapidMelts + Vitamin C,
and
Zicam Cold Remedy ChewCaps, which are oral delivery cold remedy products.
The company also offers Zicam Allergy Relief, a homeopathic nasal gel
formula to control allergy symptoms for sufferers of hay fever and upper
respiratory allergies; Zicam Extreme Congestion Relief, a nasal gel for
relief of nasal congestion and sinus pressure; Zicam Sinus Relief that
provides the benefits of the Extreme product with the aromatic strength
of
a cooling menthol/eucalyptus blend; and Nasal Comfort for nasal health.
In
addition, it offers Zicam Cough Spray products, including Zicam Cough
Mist
Max, Cough Melt product, and Cough Plus D product that are designed for
cough relief and throat irritation; and Zicam Cold and Flu Relief
products,
which utilize a spoon dosing delivery to provide relief of cold and flu
symptoms. Matrixx sells its products directly to food, drug, mass market,
and wholesale warehouse retailers in the United States, as well as to
distributors that sell to retail establishments. The company was founded
in
1991. It was formerly known as Gum Tech International, Inc. and changed
its
name to Matrixx Initiatives, Inc. in 2002. Matrixx is based in Phoenix,
Arizona.
---------------
FROM 8K CURRENT RE****T:
Favorable Jury Verdict
As previously re****ted, numerous lawsuits have been filed against
Matrixx Initiatives, Inc. (the “Company”) alleging that our Zicam Cold
Remedy nasal gel product has caused the permanent loss or diminishment of
the sense of smell or smell and taste, including Bruno vs. Matrixx
Initiatives, Inc., filed July 7, 2006 in the Superior Court of the State
of California, County of San Diego, Case No. 868821. See “Legal
Proceedings — Product Liability Matters” in Note 7 of Notes to Condensed
Consolidated Financial Statements in the Company’s Re****t on Form 10-Q
for the fiscal quarter ended December 31, 2007. Beginning on March 25,
2008, the Bruno case was tried before a jury in the Superior Court of the
State of California, San Diego County. On April 3, 2008, the jury
delivered a unanimous verdict in favor of the Company.
--------------
FROM THE 10Q QUARTERLY RE****T:
the 2007/2008 cold season is off to a slow start and the incidence of
colds and flu in the general population for the quarter ended December
31, 2007, was tracking at the lowest levels since Zicam was introduced in
1999. The low level of illness is reflected in the lower level of sales
realized during the quarter ended December 31, 2007
-----------
For the 12 weeks ended December 30, 2007, retail sales of our products
(as measured by three outlet syndicated scanner data, not including our
largest customer, Wal-Mart) decreased approximately 7% over the
comparable period in the previous year, while the entire cough and cold
category decreased approximately 5% over the same period
----------
Net sales for the three months ended December 31, 2007 were $30.8
million, or 15% below net sales of $36.2 million for the quarter ended
December 31, 2006.
Gross profit for the three months ended December 31, 2007 was
approximately $19.7 million, compared to gross profit of approximately
$23.2 million for the quarter ended December 31, 2006. The lower gross
profit is due to the decreased level of sales during the quarter
(compared to the prior year).
..
http://stockcharts.com/charts/gallery.html?MTXX
..
resistance : $15.90 & $16.50/17 wow 12y sup****t=$11.99
MIGHT BE SMART TO PLAY BOTH SIDES AND JOIN THE SHORTS
Short % of Float (as of 11-Mar-08): 9.20% <--squeezeable shorts
down to the eventual test of sup****t
and then join the short squeeze ENTRY LONG: BELOW $12
|
